RT Journal Article
SR Electronic
T1 Time-series plasma cell-free DNA analysis reveals disease severity of COVID-19 patients
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.08.20124305
DO 10.1101/2020.06.08.20124305
A1 Chen, Xinping
A1 Lin, Yu
A1 Wu, Tao
A1 Xu, Jinjin
A1 Ma, Zhichao
A1 Sun, Kun
A1 Li, Hui
A1 Luo, Yuxue
A1 Zhang, Chen
A1 Chen, Fang
A1 Wang, Jiao
A1 Kuo, Tingyu
A1 Li, Xiaojuan
A1 Geng, Chunyu
A1 Lin, Feng
A1 Huang, Chaojie
A1 Hu, Junjie
A1 Yin, Jianhua
A1 Liu, Ming
A1 Tao, Ye
A1 Zhang, Jiye
A1 Ou, Rijing
A1 Xiao, Furong
A1 Yang, Huanming
A1 Wang, Jian
A1 Xu, Xun
A1 Fu, Shengmiao
A1 Jin, Xin
A1 Jiang, Hongyan
A1 Chen, Ruoyan
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.08.20124305.abstract
AB Clinical symptoms of coronavirus disease 2019 (COVID-19) range from asymptomatic to severe pneumonia and death. Detection of individuals at high risk for critical condition is crucial for control of the disease. Herein, for the first time, we profiled and analyzed plasma cell-free DNA (cfDNA) of mild and severe COVID-19 patients. We found that in comparison between mild and severe COVID-19 patients, Interleukin-37 signaling was one of the most relevant pathways; top significantly altered genes included POTEH, FAM27C, SPATA48, which were mostly expressed in prostate and testis; adrenal glands, small intestines and liver were tissues presenting most differentially expressed genes. Our data thus revealed potential tissue involvement, provided insights into mechanism on COVID-19 progression, and highlighted utility of cfDNA as a noninvasive biomarker for disease severity inspections.One Sentence Summary CfDNA analysis in COVID-19 patients reveals severity-related tissue damage.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFunding of this work includes: 1.the Hainan Medical University novel coronavirus pneumonia project (XGZX2020002) 2. National natural science foundation of china (81960389) 3. Natural Science Foundation of Guangdong Province, China (2017A030306026) 4 Guangdong Provincial Key Laboratory of Genome Read and Write (2017B030301011) 5 Talent Support Project of Guangdong, China (2017TQ04R858) 6. Distinguished Young Scholar of South China University of China (2017JQ017).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The research was approved by ethics committee of Hainan General Hospital with NO. [2020] 138, and also approved by ethics committee of BGI-Shenzhen with NO. BGI-IRB 20046All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data that support the findings of this study have been deposited into CNGB Nucleotide Sequence Archive (https://db.cngb.org/cnsa/) with accession number CNP0001081, and the availability of the data will be confirmed as soon as approval of the study is signed by Chinese human genetic resource committee.